The evaluation of the clinical response to immunotherapy in patients with allergic rhinitis

The evaluation of the clinical response to subcutaneous immunotherapy in patients with allergic rhinitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170201032346N6

Enrollment

Registered

2020-12-30

Start date

2014-04-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis. Allergic rhinitis, unspecified

Interventions

Intervention group: Patients who has a positive prick test will undergo immunotherapy with allergen extract with three vials diluted 1:10000 pg per week for 10 sessions, 1:1000 pg every other week for

Eligibility

Sex/Gender

All

Age

5 Years to 65 Years

Inclusion criteria

Inclusion criteria: Positive Prick test (induration and erythema for more than 3mm is considered positive prick test) Allergic Rhinitis Negative pregnancy test Informed consent 5 to 65 years of age

Exclusion criteria

Exclusion criteria: Absence of concomitant viral, fungal or bacterial rhinosinusitis Autoimmune disease Malignancy Use of beta-blockers

Design outcomes

Primary

Measure	Time frame
Sneezing. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Postnasal dripping. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Nasal congestion. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Itchy throat. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Itchy eyes. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Rhinorrhea. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Cough. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Sleep disturbance. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.	—

Measure

Time frame

Sneezing. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Postnasal dripping. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Nasal congestion. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Itchy throat. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Itchy eyes. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Rhinorrhea. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Cough. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.;Sleep disturbance. Timepoint: Before intervention, 2 years after intervention. Method of measurement: Checklist containing clinical symptoms.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFirouzi Hossein

Mazandaran University of Medical Sciences

firoozihosein@mazums.ac.ir+1 155230181

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026